A prior long-acting GLP-1 therapy was withdrawn from the market due to modest effects on glucose reduction and body weight in people with type 2 diabetes, yet this same therapy reduced major adverse cardiovascular events by 22%, demonstrating cardiovascular benefits independent of metabolic improvements.
factualpending
Speaker
Unidentified Speaker — GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery [5nGTUaqKmcY]Evidence Quote
“another prior long acting gp1 therapy was withdrawn from the market owing to its modest effects on reduction of glucose and body weight in people with type two diabetes however it still reduced the rates of major adverse cardiovascular events by 22% so again in humans we see this signal where gp1s can have benefits even independent of or separable from weight loss”
Created: 8/11/2026, 7:45:10 AM
Your notes
Loading notes...